June 27, 2010- BSP announced that the CE mark was granted to its HyperQ AD-100 and HyperQ-AN products.
BSP, which develops and commercializes advanced products for the non invasive, accurate diagnosis of heart diseases, announced that its Add-On product, the HyperQ AD-100, intended for improved diagnostic performance of Stress ECG, has been granted the European CE conformance mark. The HyperQ AD-100 product is an add-on system with the HyperQ technology which is incorporated in parallel to existing standard stress ECG systems. The integration of the HyperQ AD-100 into Stress ECG systems enables accurate and sensitive diagnosis of Ischemic Heart Disease, a leading cause of death in the world.
The unique technology developed by BSP is implemented in a non invasive manner and does not involve exposure to radiation or other hazards to patients. It is highly effective in diagnosing sick people and in ruling out disease in healthy individuals. The HyperQ AD-100 enables physicians to benefit from the clinical advantages of the technology without the need to replace their existing installed Stress ECG system... BSP 's Press Release -
Blog Archive
-
▼
2010
(47)
-
▼
July
(8)
- Boston Scientific : First Patient Enrollment in Mu...
- BSP granted CE mark for its HyperQ AD-100 product ...
- Acorda Therapeutics : Receipt of NIH Grant for Dev...
- Cardiome : Investigational BRINAVESS™ (vernakalant...
- Pfizer : Caduet Reduces 10-Year Calculated Risk Of...
- St Jude Medical : Acquisition of LightLab Imaging
- Cardio3 BioSciences : Positive Three‐Month Data fr...
- Anthera Pharmaceuticals : First Patients in Pivota...
-
▼
July
(8)